Sugi Predict

Sugi Predict / Compounds / SCHEMBL1897448

SCHEMBL1897448

SCHEMBL1897448

Cc1ccc2nc(-c3ccccc3)cc(C(=O)Nc3nnc(-c4ccco4)o3)c2c1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STAT3 P40763 9/20 0.81
▸ RAB9A P51151 3/20 0.59
▸ NPC1 O15118 2/20 0.59
▸ LMNA P02545 7/20 0.58
▸ SMN1; SMN2 Q16637 3/20 0.58
▸ ALOX12 P18054 2/20 0.58
▸ KMT2A Q03164 3/20 0.57
▸ KDM4E B2RXH2 5/20 0.55
▸ ALDH1A1 P00352 3/20 0.55
▸ HSD17B10 Q99714 1/20 0.55
▸ MEN1 O00255 2/20 0.55
▸ HTT P42858 2/20 0.55
▸ TDP1 Q9NUW8 2/20 0.55
▸ CHEK1 O14757 1/20 0.55
▸ AURKA O14965 1/20 0.55
▸ DAPK3 O43293 1/20 0.55
▸ PRKD3 O94806 1/20 0.55
▸ PAK4 O96013 1/20 0.55
▸ NTRK1 P04629 1/20 0.55
▸ RET P07949 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1904403 0.94 STAT3 (0.82) STAT3RAB9ANPC1LMNASMN1; SMN2
SCHEMBL1898648 0.91 STAT3 (0.87) STAT3RAB9ANPC1LMNASMN1; SMN2
SCHEMBL1905449 0.91 STAT3 (0.84) STAT3RAB9ANPC1LMNASMN1; SMN2
SCHEMBL1900395 0.90 STAT3 (0.82) STAT3RAB9ANPC1LMNASMN1; SMN2
SCHEMBL1899809 0.89 STAT3 (1.00) STAT3RAB9ANPC1LMNASMN1; SMN2
SCHEMBL29382140 0.89 STAT3 (1.00) STAT3RAB9ANPC1LMNASMN1; SMN2
SCHEMBL1900513 0.89 STAT3 (0.81) STAT3RAB9ANPC1LMNASMN1; SMN2
SCHEMBL1896601 0.89 STAT3 (0.81) STAT3RAB9ANPC1LMNASMN1; SMN2
SCHEMBL1898201 0.89 STAT3 (0.81) STAT3RAB9ANPC1LMNASMN1; SMN2
SCHEMBL1904300 0.89 STAT3 (0.81) STAT3RAB9ANPC1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2325181-B1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) 2017-03-29 — — EP disclosed
US-8466290-B2 STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) 2013-06-18 — — US disclosed
US-20110172429-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) 2011-07-14 — — US disclosed
EP-2325181-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT Pharma Ip General Incorporated Association (JP) 2011-05-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172429-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT STAT3, STAT4, STAT5B STAT3 1/4885RAB9A 2148/4885NPC1 3304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.